PL1803468T3 - Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej - Google Patents

Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej

Info

Publication number: PL1803468T3
Authority: PL; Poland
Prior art keywords: agents; optic neuropathy; retinopathy; nrf2; metabolites
Prior art date: 2003-12-22

Application number

PL07105047T

Other languages

English (en)

Inventor

Robert Landers

Iok-Hou Pang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-22

Filing date

2004-12-17

Publication date

2012-05-31

2004-12-17 Application filed by Novartis Ag filed Critical Novartis Ag

2012-05-31 Publication of PL1803468T3 publication Critical patent/PL1803468T3/pl

Links

206010061323 Optic neuropathy Diseases 0.000 title abstract 2
208000017442 Retinal disease Diseases 0.000 title abstract 2
206010038923 Retinopathy Diseases 0.000 title abstract 2
208000020911 optic nerve disease Diseases 0.000 title abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 3
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 abstract 2
101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 abstract 2
102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 abstract 1
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 abstract 1
LZENMJMJWQSSNJ-UHFFFAOYSA-N 3H-1,2-dithiole-3-thione Chemical compound S=C1C=CSS1 LZENMJMJWQSSNJ-UHFFFAOYSA-N 0.000 abstract 1
239000004255 Butylated hydroxyanisole Substances 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
239000004258 Ethoxyquin Substances 0.000 abstract 1
238000006845 Michael addition reaction Methods 0.000 abstract 1
GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 abstract 1
235000019282 butylated hydroxyanisole Nutrition 0.000 abstract 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 1
229940043253 butylated hydroxyanisole Drugs 0.000 abstract 1
230000001120 cytoprotective effect Effects 0.000 abstract 1
230000007123 defense Effects 0.000 abstract 1
239000012039 electrophile Substances 0.000 abstract 1
235000019285 ethoxyquin Nutrition 0.000 abstract 1
DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 abstract 1
229940093500 ethoxyquin Drugs 0.000 abstract 1
229930003935 flavonoid Natural products 0.000 abstract 1
150000002215 flavonoids Chemical class 0.000 abstract 1
235000017173 flavonoids Nutrition 0.000 abstract 1
150000002540 isothiocyanates Chemical class 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000005937 nuclear translocation Effects 0.000 abstract 1
239000007800 oxidant agent Substances 0.000 abstract 1
230000037361 pathway Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
239000003053 toxin Substances 0.000 abstract 1
239000002676 xenobiotic agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Ophthalmology & Optometry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Otolaryngology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Saccharide Compounds (AREA)
Quinoline Compounds (AREA)
Pyrane Compounds (AREA)
Pyrrole Compounds (AREA)

PL07105047T 2003-12-22 2004-12-17 Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej PL1803468T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US53177003A	2003-12-22	2003-12-22
US53177003P	2003-12-22	2003-12-22
EP04814825A EP1696958B1 (en)	2003-12-22	2004-12-17	Agents for treatment of glaucomatous retinopathy and optic neuropathy
EP07105047A EP1803468B1 (en)	2003-12-22	2004-12-17	Agents for treatment of glaucomatours retinopathy and optic neuropathy

Publications (1)

Publication Number	Publication Date
PL1803468T3 true PL1803468T3 (pl)	2012-05-31

Family

ID=34738696

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL04814825T PL1696958T3 (pl)	2003-12-22	2004-12-17	Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej
PL07105047T PL1803468T3 (pl)	2003-12-22	2004-12-17	Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL04814825T PL1696958T3 (pl)	2003-12-22	2004-12-17	Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej

Country Status (19)

Country	Link
US (2)	US20050137146A1 (pl)
EP (2)	EP1696958B1 (pl)
JP (2)	JP4755599B2 (pl)
KR (1)	KR20060127043A (pl)
CN (1)	CN1897972A (pl)
AT (2)	ATE357932T1 (pl)
AU (1)	AU2004308919B2 (pl)
BR (1)	BRPI0417987A (pl)
CA (1)	CA2547852A1 (pl)
CY (2)	CY1106623T1 (pl)
DE (1)	DE602004005617T2 (pl)
DK (2)	DK1696958T3 (pl)
ES (2)	ES2282926T3 (pl)
MX (1)	MXPA06006980A (pl)
PL (2)	PL1696958T3 (pl)
PT (2)	PT1696958E (pl)
SI (2)	SI1803468T1 (pl)
WO (1)	WO2005063295A1 (pl)
ZA (1)	ZA200604862B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6881198B2 (en) *	2001-01-09	2005-04-19	J. David Brown	Glaucoma treatment device and method
ATE357932T1 (de) *	2003-12-22	2007-04-15	Alcon Inc	Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
WO2005102345A1 (en) *	2004-03-30	2005-11-03	Alcon, Inc.	Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
WO2006030907A1 (ja) *	2004-09-16	2006-03-23	Redox Bioscience Inc.	網膜保護剤
WO2007035356A2 (en) *	2005-09-16	2007-03-29	Bg Implant, Inc.	Glaucoma treatment devices and methods
WO2008016095A1 (en) *	2006-08-02	2008-02-07	Santen Pharmaceutical Co., Ltd.	PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT
WO2008108825A2 (en) *	2006-10-10	2008-09-12	Burnham Institute For Medical Research	Neuroprotective compositions and methods
JP2008247898A (ja) *	2007-03-08	2008-10-16	Santen Pharmaceut Co Ltd	トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
RS58392B1 (sr)	2008-04-18	2019-04-30	Reata Pharmaceuticals Inc	Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17
TW201006474A (en)	2008-04-18	2010-02-16	Reata Pharmaceuticals Inc	Natural products including an anti-flammatory pharmacore and methods of use
HUE033288T2 (en)	2008-04-18	2017-11-28	Reata Pharmaceuticals Inc	Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives
AU2011240690C1 (en)	2010-04-12	2014-11-06	Reata Pharmaceuticals Holdings, LLC	Method of treating obesity using antioxidant inflammation modulators
RU2472475C2 (ru) *	2010-04-20	2013-01-20	Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ)	Способ комбинированного лечения глаукомной оптической нейропатии
US20130288985A1 (en) *	2010-07-15	2013-10-31	The Schepens Eye Research Institute Inc.	Compositions and methods of treatment of corneal endothelium disorders
RU2447864C1 (ru) *	2010-09-15	2012-04-20	Инна Витальевна Щербинина	Способ лечения заболеваний зрительного нерва и сетчатки
AU2012272924A1 (en)	2011-06-21	2014-01-16	The Johns Hopkins University	Compounds for treating peripheral neuropathies and other neurodegenerative disorders
RU2546019C2 (ru) *	2013-03-02	2015-04-10	Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации	Способ лечения глаукомной оптической нейропатии
EP2991621B1 (en) *	2013-05-02	2020-12-09	Retina Foundation of the Southwest	Two-layer ocular implant
JP7030516B2 (ja)	2014-12-31	2022-03-07	マイクロオプティクスインコーポレイテッド	緑内障治療装置および方法
JP6892693B2 (ja)	2015-09-30	2021-06-23	マイクロオプティクスインコーポレイテッド	ドライアイ治療装置および方法
EP3509642A1 (en)	2016-09-12	2019-07-17	ST IP Holding AG	Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
AU2017322544B2 (en)	2016-09-12	2022-06-02	St Ip Holding Ag	Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
BR112019009256A2 (pt)	2016-11-08	2019-07-16	Reata Pharmaceuticals, Inc.	métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
RU2647324C1 (ru) *	2017-04-24	2018-03-15	Игорь Евгеньевич Хаценко	Способ определения показаний для лечения амблиопии с помощью нейропептидного препарата
WO2021195876A1 (zh) *	2020-03-30	2021-10-07	武汉纽福斯生物科技有限公司	一种人核因子e2相关因子2的表达载体及其应用
US11135220B1 (en)	2020-04-08	2021-10-05	St Ip Holding Ag	Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
WO2023133502A1 (en) *	2022-01-07	2023-07-13	The Johns Hopkins University	Treatment and prevention of trigeminal neuralgia

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4456757A (en) *	1981-03-20	1984-06-26	Asahi Kasei Kogyo Kabushiki Kaisha	Isoquinolinesulfonyl derivatives and process for the preparation thereof
US4678783B1 (en) *	1983-11-04	1995-04-04	Asahi Chemical Ind	Substituted isoquinolinesulfonyl compounds
US4959389A (en) *	1987-10-19	1990-09-25	Speiser Peter P	Pharmaceutical preparation for the treatment of psoriatic arthritis
US5124154A (en) *	1990-06-12	1992-06-23	Insite Vision Incorporated	Aminosteroids for ophthalmic use
AU689036B2 (en) *	1995-05-10	1998-03-19	Kureha Chemical Industry Co., Ltd.	Pharmaceutical composition containing substance inhibiting HSP47 production
JP3193301B2 (ja) *	1995-09-14	2001-07-30	麒麟麦酒株式会社	生理活性タンパク質ｐ１６０
US5906819A (en) *	1995-11-20	1999-05-25	Kirin Beer Kabushiki Kaisha	Rho target protein Rho-kinase
US5681854A (en) *	1995-11-22	1997-10-28	Alcon Laboratories, Inc.	Use of aliphatic carboxylic acid derivatives in ophthalmic disorders
JP3719609B2 (ja) *	1995-12-21	2005-11-24	アルコンラボラトリーズ，インコーポレイテッド	緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用
PT885888E (pt) *	1996-02-02	2003-12-31	Western Therapeutics Inst D	Derivados e farmacos de isoquinolina
US6586425B2 (en) *	1996-02-21	2003-07-01	Wisconsin Alumni Research Foundation	Cytoskeletal active agents for glaucoma therapy
JP3872834B2 (ja) *	1996-03-04	2007-01-24	第一製薬株式会社	メイラード反応抑制剤
PT956865E (pt) *	1996-08-12	2007-07-30	Mitsubishi Pharma Corp	Medicamentos compreendendo inibidores da rho cinase.
US5759787A (en) *	1996-08-26	1998-06-02	Tularik Inc.	Kinase assay
JP2002501482A (ja) *	1997-01-16	2002-01-15	ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド	抗酸化剤との相乗的相互作用を通じて多環式フェノール化合物の細胞保護効果を強化するための組成物
US6573044B1 (en) *	1997-08-07	2003-06-03	The Regents Of The University Of California	Methods of using chemical libraries to search for new kinase inhibitors
US6441033B1 (en) *	1997-12-22	2002-08-27	Alcon Manufacturing, Ltd.	11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists
US6274338B1 (en) *	1998-02-24	2001-08-14	President And Fellows Of Harvard College	Human c-Maf compositions and methods of use thereof
WO1999043315A1 (en) *	1998-02-25	1999-09-02	Shionogi & Co., Ltd.	Therapeutic agent for complication of diabetes
US20010041174A1 (en) *	1998-11-24	2001-11-15	Najam Sharif	Use of implanted encapsulated cells expressing glutamate transporter proteins for the treatment of neurodegenerative diseases
US6020383A (en) *	1999-01-11	2000-02-01	Eastman Chemicals Company	Method for reducing blood cholesterol and/or blood triglycerides
US6103756A (en) *	1999-08-11	2000-08-15	Vitacost Inc.	Ocular orally ingested composition for prevention and treatment of individuals
US6573299B1 (en) *	1999-09-20	2003-06-03	Advanced Medical Instruments	Method and compositions for treatment of the aging eye
AU2001271824A1 (en) *	2000-07-05	2002-01-14	Johns Hopkins School Of Medicine	Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
GB0030727D0 (en) *	2000-12-15	2001-01-31	Lumitech Uk Ltd	Methods and kits for detecting kinase activity
US6756063B2 (en) *	2001-03-29	2004-06-29	Zoltan Laboratories, Llc	Methods and compositions for the treatment of human and animal cancers
CA2357265C (en) *	2001-04-24	2004-04-13	University Of British Columbia	Improved additive for livestock feeds
US6884816B2 (en) *	2001-08-31	2005-04-26	Alcon, Inc.	Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
TW201041580A (en) *	2001-09-27	2010-12-01	Alcon Inc	Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
US7199122B2 (en) *	2001-10-02	2007-04-03	Fox Chase Cancer Center	Methods for inhibiting angiogenesis
US7407986B2 (en) *	2001-12-18	2008-08-05	Brassica Foundation For Chemoprotection Research, Inc.	Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
AU2003205737A1 (en) *	2002-02-15	2003-09-04	Humboldt Universitaet	Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
US20030219846A1 (en) *	2002-02-28	2003-11-27	Pfizer Inc.	Assay for activity of the ActRIIB kinase
WO2004012677A2 (en) *	2002-08-05	2004-02-12	Wackvom, Ltd.	Methods and compositions to treat conditions associated with neovascularization
US6747025B1 (en) *	2002-11-27	2004-06-08	Allergan, Inc.	Kinase inhibitors for the treatment of disease
TW200526224A (en) *	2003-12-22	2005-08-16	Alcon Inc	Short form c-Maf transcription factor antagonists for treatment of glaucoma
CA2548146A1 (en) *	2003-12-22	2005-07-14	Alcon, Inc.	Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
ATE357932T1 (de) *	2003-12-22	2007-04-15	Alcon Inc	Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie

2004
- 2004-12-17 AT AT04814825T patent/ATE357932T1/de active
- 2004-12-17 EP EP04814825A patent/EP1696958B1/en not_active Expired - Lifetime
- 2004-12-17 BR BRPI0417987-0A patent/BRPI0417987A/pt not_active IP Right Cessation
- 2004-12-17 EP EP07105047A patent/EP1803468B1/en not_active Expired - Lifetime
- 2004-12-17 ZA ZA200604862A patent/ZA200604862B/en unknown
- 2004-12-17 JP JP2006545535A patent/JP4755599B2/ja not_active Expired - Fee Related
- 2004-12-17 PL PL04814825T patent/PL1696958T3/pl unknown
- 2004-12-17 MX MXPA06006980A patent/MXPA06006980A/es active IP Right Grant
- 2004-12-17 PL PL07105047T patent/PL1803468T3/pl unknown
- 2004-12-17 ES ES04814825T patent/ES2282926T3/es not_active Expired - Lifetime
- 2004-12-17 ES ES07105047T patent/ES2371364T3/es not_active Expired - Lifetime
- 2004-12-17 SI SI200431767T patent/SI1803468T1/sl unknown
- 2004-12-17 DK DK04814825T patent/DK1696958T3/da active
- 2004-12-17 AU AU2004308919A patent/AU2004308919B2/en not_active Ceased
- 2004-12-17 SI SI200430296T patent/SI1696958T1/sl unknown
- 2004-12-17 CA CA002547852A patent/CA2547852A1/en not_active Abandoned
- 2004-12-17 PT PT04814825T patent/PT1696958E/pt unknown
- 2004-12-17 CN CNA2004800384580A patent/CN1897972A/zh active Pending
- 2004-12-17 US US11/015,888 patent/US20050137146A1/en not_active Abandoned
- 2004-12-17 DE DE602004005617T patent/DE602004005617T2/de not_active Expired - Lifetime
- 2004-12-17 PT PT07105047T patent/PT1803468E/pt unknown
- 2004-12-17 KR KR1020067014097A patent/KR20060127043A/ko not_active Ceased
- 2004-12-17 DK DK07105047.0T patent/DK1803468T3/da active
- 2004-12-17 WO PCT/US2004/042687 patent/WO2005063295A1/en not_active Ceased
- 2004-12-17 AT AT07105047T patent/ATE523208T1/de active
2007
- 2007-05-25 CY CY20071100711T patent/CY1106623T1/el unknown
2010
- 2010-11-04 JP JP2010247809A patent/JP2011046736A/ja not_active Withdrawn
2011
- 2011-02-22 US US13/031,742 patent/US20110144127A1/en not_active Abandoned
- 2011-11-24 CY CY20111101143T patent/CY1112393T1/el unknown

Also Published As

Publication number	Publication date
ATE523208T1 (de)	2011-09-15
PT1696958E (pt)	2007-06-04
SI1803468T1 (sl)	2011-12-30
KR20060127043A (ko)	2006-12-11
MXPA06006980A (es)	2006-12-14
JP2011046736A (ja)	2011-03-10
DE602004005617D1 (de)	2007-05-10
DE602004005617T2 (de)	2007-12-13
PT1803468E (pt)	2011-11-23
WO2005063295A1 (en)	2005-07-14
EP1803468A1 (en)	2007-07-04
PL1696958T3 (pl)	2007-08-31
SI1696958T1 (sl)	2007-08-31
US20050137146A1 (en)	2005-06-23
EP1696958B1 (en)	2007-03-28
CA2547852A1 (en)	2005-07-14
HK1097179A1 (en)	2007-06-22
ES2371364T3 (es)	2011-12-30
AU2004308919B2 (en)	2009-11-12
AU2004308919A1 (en)	2005-07-14
JP2007515423A (ja)	2007-06-14
EP1803468B1 (en)	2011-09-07
BRPI0417987A (pt)	2007-04-27
CN1897972A (zh)	2007-01-17
DK1696958T3 (da)	2007-07-09
DK1803468T3 (da)	2011-12-05
ZA200604862B (en)	2007-10-31
EP1696958A1 (en)	2006-09-06
ES2282926T3 (es)	2007-10-16
US20110144127A1 (en)	2011-06-16
HK1110772A1 (en)	2008-07-25
ATE357932T1 (de)	2007-04-15
JP4755599B2 (ja)	2011-08-24
CY1106623T1 (el)	2012-01-25
CY1112393T1 (el)	2015-12-09

Publication	Publication Date	Title
SI1803468T1 (sl)	2011-12-30	Sredstva za zdravljenje glavkomatozne retinopatije in optične nevropatije
PT762837E (pt)	2002-07-31	Processo para melhorar a durabilidade e/ou estabilizacao de produtos degradaveis microbiologicamente
ATE505201T1 (de)	2011-04-15	Enzymbehandlung von nahrungsmitteln für zöliakie- sprue
BRPI0417996A (pt)	2007-04-27	agentes para tratamento de retinopatia diabética e formação de gánglios em degeneração macular
CY1107181T1 (el)	2012-10-24	Συνδυασμος ζιζανιοκτονων με ακυλιωμενες αμινοφαινυλοσουλφονυλουριες
DE602004008105D1 (de)	2007-09-20	42-o-alkoxyalkylrapamycinderivate und diese enthaltende zusammensetzungen
BR0014214A (pt)	2004-09-08	Imidazoquinolinas substituìdas com amida
NO20033664D0 (no)	2003-08-19	Mikroorganisme for biologisk detoksifisering av mykotoksiner, dvs okratoksiner og/eller zearleoner, så vel som fremgangsmåte og anvendelsederav
DE60229922D1 (de)	2009-01-02	Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
BRPI0416752A (pt)	2007-02-27	composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
DE69731368D1 (de)	2004-12-02	Mittel zum schutz von nervenzellen
ATE334978T1 (de)	2006-08-15	Zusammensetzungen und therapeutische anwendungen von isoflavonen und deren analoga
BR0314419A (pt)	2005-07-19	Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
AR032548A1 (es)	2003-11-12	Metodo y composicion para desinfectar una superficie contaminada con una proteina prion
WO2005048920A3 (en)	2007-03-01	Methods and compositions for protecting against cataract development associated with vitrectomies
EP1478660A4 (en)	2005-02-09	KAPPA-PVIIA-RELATED CONOTOXINS AS ORGAN PROTECTIVE AGENTS
BR0313186A (pt)	2005-06-21	Agente redutor de colesterol proveniente de fibra alimentar e substâncias redutoras de colesterol
GB0623258D0 (en)	2007-01-03	Thiadiazole derivatives for the treatment of neuro-degenerative diseases
ES2036238T3 (es)	1993-05-16	Derivados de hidroxietil-azolilo.
ATE526992T1 (de)	2011-10-15	Methode zum schutz therapeutischer zusammensetzungen von hostvermittelter inaktivierung
ES2062570T3 (es)	1994-12-16	L-alfa-glicerofosforil-d-mio-inositol para el tratamiento de neuropatias perifericas y de cerebropatias.
ES2159622T3 (es)	2001-10-16	Derivado del diazacicloalcanoalquilsulfonamida.
AR034508A1 (es)	2004-02-25	Agente protector de las neuronas retinales.
GT200000136A (es)	2002-02-01	Gen de streptomyces avermitilis que dirige la relacion de avermectinas b2 : b1 (2).
BR0215752A (pt)	2005-03-29	Piranoindazóis e seu uso no tratamento de glaucoma